Page 1,934«..1020..1,9331,9341,9351,936..1,9401,950..»

Bubble Boy Disease Cured With Stem Cells

Posted: November 19, 2014 at 2:45 pm

TIME Health medicine Bubble Boy Disease Cured With Stem Cells Alysia Padilla-Vacarro and daughter Evangelina on the day of her gene therapy treatment. Evangelina, now two years old, has had her immune system restored and lives a healthy and normal life. Courtesy of UCLA Researchers have treated more than two dozen patients with a treatment made from their own bone marrow cells

Alysia Padilla-Vacarro and Christian Vacarro owe their daughters life to stem cells. Evangelina, now two, is alive today because she saved herself with her own bone marrow cells.

Evangelina, a twin, was born with a severe immune disorder caused by a genetic aberration that makes her vulnerable to any and all bacteria and viruses; even a simple cold could be fatal. But doctors at University of California Los Angeles (UCLA) Broad Stem Cell Research Center gave her a new treatment, using her own stem cells, that has essentially cured her disease. Shes one of 18 children who have been treated with the cutting-edge therapy, and the studys leader, Dr. Donald Kohn, says that the strategy could also be used to treat other gene-based disorders such as sickle cell anemia.

Known to doctors as adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID), its better known as bubble boy disease, since children born with the genetic disorder have immune systems so weak that they need to stay in relatively clean and germ-free environments. Until Evangelina and her sister Annabella were 11 months old, We were gowned and masked and did not go outside, says their mother Alysia Padilla-Vaccaro. Our children did not physically see our mouths until then because we were masked all the time. We couldnt take them outside to take a breath of fresh air, because there is fungus in the air, and that could kill her.

Both parents wore masks at work to lower the chances they would be exposed to germs that they might bring back home. And they took showers and changed clothes as soon as they entered the house.

MORE: Gene-Therapy Trial Shows Promise Fighting Bubble Boy Syndrome

SCID is caused by a genetic mutation in the ADA gene, which normally produces the white blood cells that are the front lines of the bodys defense against bacteria and viruses. The Vaccaros decided to treat Annabella in the same way that they cared for Evangelina; They were crawling and playing with each other, and every toy they sucked on, they stuck in each others hands and each others mouth, so we couldnt take one outside to have a grand old time and potentially bring something back that could harm her sister, says Padilla-Vaccaro.

The only treatments for SCID are bone marrow transplants from healthy people, ideally a matched sibling; the unaffected cells can then repopulate the immune system of the baby with SCID. But despite being her twin, Annabella wasnt a blood match for her sister, nor were her parents. Padilla-Vaccaro and her husband, Christian, were considering unrelated donors but were concerned about the risk of rejection. We would be trying to fix one problem and getting another, she says.

MORE: Stem Cells Allow Nearly Blind Patients to See

Thats when the doctors at the Childrens Hospital at Orange County, where Evangelina was diagnosed, told her parents about a stem cell trial for SCID babies at UCLA, led by Dr. Donald Kohn. As soon as they said trial, I thought, my kid is dead, says Padilla-Vaccaro of the last resort option. But a dozen children born with other forms of SCIDin which different mutations caused the same weak immune systemswho were successfully treated by Kohn convinced the couple that the therapy was worth trying. Kohn had one spot left in the trial and was willing to hold it for Evangelina until she matured more. Born premature, she was diagnosed at six weeks old and needed more time for what was left of her immune system to catch up to weather the procedure.

Visit link:
Bubble Boy Disease Cured With Stem Cells

Posted in Gene therapy | Comments Off on Bubble Boy Disease Cured With Stem Cells

UCLA Doctors Hail Potential Cure For Bubble Baby Syndrome

Posted: November 19, 2014 at 2:41 pm

CBS Los Angeles (con't)

Affordable Care Act Updates: CBSLA.com/ACA

Health News & Information: CBSLA.com/Health

WESTWOOD (CBSLA.com) Doctors say a groundbreaking stem cell therapy treatment out of UCLA may have cured Bubble Baby syndrome once and for all.

KNX 1070s Brian Ping reports Dr. Donald Kohn has perfected a gene therapy that has now cured 18 children born without an immune system, known as ADA-deficient severe combined immunodeficiency (SCID).

Only weeks after giving birth to fraternal twins in 2012, Alysia and Christian Padilla-Vaccaro found out their daughter Evangelinas immune system was so deficient that she could have no exposure to the outside world.

After enrolling their daughter in Dr. Donald Kohns revolutionary stem cell gene therapy treatment which was nearly three decades in the making doctors extracted stem cells from the bone marrow in Evangelinas hip, then used a modified mouse virus to correct her faulty gene before replacing the marrow.

You hear the words mouse virus and you want to run the other way, said mom Alysia. But they modify it so that its teaching it to do something that they want it to do, which is put something in there that was missing.

Evangelinas new immune system developed without side effects and she is now living a healthy normal life.

Her mother Alysia said while the process was difficult for any mom to go through, it was all worth it.

Link:
UCLA Doctors Hail Potential Cure For Bubble Baby Syndrome

Posted in Stem Cell Therapy | Comments Off on UCLA Doctors Hail Potential Cure For Bubble Baby Syndrome

Establishment of induced pluripotent stem cells from Werner syndrome fibroblasts

Posted: November 18, 2014 at 2:54 pm

4 hours ago

Associate Professor Akira Shimamoto and Professor Hidetoshi Tahara at the Graduate School of Biomedical & Health Science in Hiroshima University, Professor Koutaro Yokote at the Graduate School of Medicine in Chiba University, Visiting Professor Makoto Goto at the Medical Center East in Tokyo Women's Medical University, and collaborators including the staff at the Cancer Chemotherapy Center in the Japanese Foundation for Cancer Research, Tottori University, and Keio University established induced pluripotent stem (iPS) cells from the fibroblasts of Werner Syndrome patients.

These results were published in PLOS ONE in an article entitled "Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture."

Werner syndrome is characterized by the premature appearance of features associated with normal aging and cancer predisposition. This syndrome occurs frequently in Japan, affecting 1 in 20,000 to 1 in 40,000 people. The therapeutic methods for this disease are very limited and it is expected that iPS cells can be used for the development of innovative therapies.

Dr. Shimamoto and his collaborators analyzed patient-derived iPS cells and found that telomeric abnormalities in the fibroblasts of these patients, which were caused by the lack of WRN helicase encoded by the gene responsible for Werner syndrome, were recovered in the iPS cells generated from these patients. Furthermore, Dr. Shimamoto found that the expression levels of aging-related genes, including those encoding cell cycle inhibitors and inflammatory cytokines, in the patient-derived iPS cells were the same as those in normal iPS cells, even though the expression levels of these genes in the fibroblasts of the patients were higher than those in normal fibroblasts.

Dr. Shimamoto said, "So far, the use of patient cells was restricted to blood or dermal cells in basic research. The iPS cells that we have established will provide an opportunity for drug discovery for the treatment of Werner syndrome and also help with better understanding of the mechanism of this disease. In addition, the mutated WRN gene in patient-derived iPS cells can be corrected by genome editing. This advantage will be help in the development of new gene and cell therapies for Werner syndrome."

Explore further: Scientists find that SCNT derived cells and IPS cells are similar

Journal reference: PLoS ONE

Provided by Hiroshima University

A team led by New York Stem Cell Foundation (NYSCF) Research Institute scientists conducted a study comparing induced pluripotent stem (iPS) cells and embryonic stem cells created using somatic cell nuclear transfer (SCNT). ...

See the article here:
Establishment of induced pluripotent stem cells from Werner syndrome fibroblasts

Posted in Stem Cells | Comments Off on Establishment of induced pluripotent stem cells from Werner syndrome fibroblasts

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

Posted: November 18, 2014 at 2:47 pm

NEW YORK (TheStreet) -- Shares ofNeoStem (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesdayafter the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.

NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy.The stem-cell therapy comesfrom a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.

NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.

Must Read:NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more:
NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

Posted in Cell Therapy | Comments Off on NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

Professor Karussis talk on stem cells trial in American Academy of Neurology – Video

Posted: November 18, 2014 at 2:41 pm


Professor Karussis talk on stem cells trial in American Academy of Neurology
Profeesor Karussis talk on stem cells.

By: Dimitrios Karussis

Read more:
Professor Karussis talk on stem cells trial in American Academy of Neurology - Video

Posted in Stem Cell Videos | Comments Off on Professor Karussis talk on stem cells trial in American Academy of Neurology – Video

Bone marrow registration drive to be held at Saint Mary's College

Posted: November 18, 2014 at 6:57 am

NOTRE DAME - You could be a life saver!

On Friday, November 21, 2014, the Saint Mary's College student club SMC Stands Up To Cancer will hold a bone marrow registration drive on campus.

It'll take place from 11am to 3pm in Reignbeaux Lounge in Le Mans Hall. For a campus map click here.

To participate, you must be between the ages of 18 and 44. It's completely painless to sign up, requiring just a swab of the inside of your cheek to get a sample of cells.

Your genetic information will be added to the Be the Match marrow database, which searches for possible matches for blood cancer patients. Suitable donors can provide bone marrow or peripheral blood stem cells to patients, saving lives.

This will be the second annual bone marrow drive held on Saint Mary's campus. Typically, one person in 540 is a match for a patient with a blood cancer. But a match surfaced out of the 50 registered on campus at the last drive. Allison Lukomski '16, a communicative sciences and disorders major, was a match for a female cancer patient. Lukomski donated peripheral blood stem cells over fall break through a non-surgical procedure.

The bone marrow registration event comes on the heels of the Pink Party Zumbathon, hosted by SMC Stands Up to Cancer, which raised money for cancer research through the national organization Stand Up To Cancer.

Original post:
Bone marrow registration drive to be held at Saint Mary's College

Posted in Michigan Stem Cells | Comments Off on Bone marrow registration drive to be held at Saint Mary's College

Reprogramming cells, long term

Posted: November 18, 2014 at 6:57 am

Harvard Stem Cell Institute (HSCI) researchers, representing five Harvard departments and affiliated institutions as well as the Massachusetts Institute of Technology (MIT), have demonstrated that adult cells, reprogrammed into another cell type in a living animal, can remain functional over a long period.

The work by Joe Zhou, an associate professor in Harvard's Department of Stem Cell and Regenerative Biology, and his collaborators is an important advance in the effort to develop cell-based therapies for tissue repair, and specifically in the effort to develop improved treatment for diabetes.

The researchers used a combination of genes to change pancreatic exocrine cells -- one of the main forms of cells in the pancreas -- in adult mice that have diabetes into insulin-producing beta cells that appeared to cure about a third of the mice of the metabolic disease, and improved insulin production in most of the other mice.

A report on the work was published today in the journal Nature Biotechnology.

The new findings are a major advance in work by HSCI co-director Doug Melton and Zhou, who in 2008 reported having converted exocrine cells into functional beta cells in mice. At that time, however, it was not known how long, and how well, the repurposed cells would function.

"The efficiency of reprogramming has always been an issue," Zhou said. "Until now, the new cells have either dropped dramatically in number or disappeared completely," he said, noting that since his work with Melton in 2008 there have been reports published in other programing systems that question whether the reprogrammed cells could be stable enough ultimately to be useful.

"What we have demonstrated is that yes, the reprogrammed cells can be useful, and for that to happen you have to create a niche environment in which the cells can survive," Zhou continued. "We have improved the reprogramming efficiency to a point where one can create a large enough number of the new cells that the new cells create their own niche environment."

Zhou said that the researchers studied the mice for up to about 13 months, approximately half their normal life span, and found that "the cells are still there, and fairly robust. These are diabetic animals, and we were able to, I wouldn't use the word 'cure' because that's a very freighted word for me to use, but they became highly glycemic animals -- though not every animal became normal. That may be because to completely control the glucose level of the animal, you not only need beta cells, you need about a quarter of a million functional beta cells. If you are short of this number, even if the beta cells are perfectly normal," they can't completely control blood sugar levels, Zhou said.

When discussing the implications of the study for the field of cellular reprogramming, Zhou cautioned that the pancreas has a particularly simple cellular organization and structure, and thus findings in the pancreas might not necessarily apply to other organs.

Diabetes is a metabolic disease that is seen in two basic forms.

View post:
Reprogramming cells, long term

Posted in Massachusetts Stem Cells | Comments Off on Reprogramming cells, long term

Anti-Leukemia Drug May Also Work Against Ovarian Cancer

Posted: November 18, 2014 at 6:54 am

Contact Information

Available for logged-in reporters only

Newswise An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

The findings extend the anti-cancer potential of an experimental monoclonal antibody called cirmtuzumab, developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, and colleagues. Cirmtuzumab is currently in a first-in-human phase 1 clinical trial to assess its safety and efficacy in treating CLL.

Cirmtuzumab targets ROR1, a protein used by embryonic cells during early development and exploited by cancer cells to promote tumor growth and metastasis, the latter being responsible for 90 percent of all cancer-related deaths.

Because normal adult cells do not express ROR1, scientists suspect ROR1 is a specific biomarker of cancer cells in general and cancer stem cells in particular. Because it appears to drive tumor growth and disease spread, they believe it also presents an excellent target for anti-cancer therapies. Earlier research by Kipps and colleagues has shown a link between ROR1 and both breast cancer and CLL.

In their latest PNAS paper, Kipps and colleagues investigated whether cirmtuzumab also might be effective against ovarian cancer, which has rebuffed efforts to find a cure or long-term remedy. Most ovarian cancer patients initially respond well to standard chemotherapy, sometimes appearing to become disease-free, but 85 percent relapse within two years after systemic treatment, often with a more aggressive and disseminated form of the disease.

More than 21,000 women are diagnosed with ovarian cancer annually; more than 14,000 die from the disease each year. The 5-year survival rate after diagnosis is 44.6 percent.

The Moores Cancer Center team found that ovarian cancer stem cells, which are thought to be responsible for cancer recurrence and metastasis and are largely resistant to standard chemotherapies, singularly express ROR1. Patients whose tumors had high levels of ROR1 experienced more aggressive forms of ovarian cancer. They had higher rates of relapse and shorter median survival times than patients with lower levels of ROR1.

ROR1 is used by embryo cells to migrate and to develop new organs, said Kipps. Cancer stem cells subsequently use ROR1 for their own growth and dissemination throughout the body. They are essentially the seeds of the cancer. The more seeds a tumor has, the greater its ability to recur after therapy or metastasize.

Link:
Anti-Leukemia Drug May Also Work Against Ovarian Cancer

Posted in California Stem Cells | Comments Off on Anti-Leukemia Drug May Also Work Against Ovarian Cancer

Programs – Cell and Regenerative Biology, University of …

Posted: November 18, 2014 at 6:52 am

Developmental and Regenerative Biology graduate program

The Department of Cell and Regenerative Biology is pleased to announce the establishment of a new graduate program (Fall 2012) to provide training in the areas of Developmental and Regenerative Biology (DRB). Students admitted via other Ph.D. programs (UW Graduate School Admissions) will fulfill the requirements of the admitting program in parallel to the DRB curriculum in order to receive a Ph.D. from the admitting program in addition to a certificate in Developmental and Regenerative Biology. Core DRB courses include: 1) Fundamentals of Stem Cell Biology and 2) Stem Cells and Regenerative Biosciences Roundtable. Electives include: 1) Mammalian Embryology and 2) Molecular and Cellular Organogenesis. For additional information contact the DRB program chair, Grace Boekhoff-Falk (boekhofffalk@wisc.edu).

Figure (right): Neural stem cells (arrowheads) and newly born neurons (arrow) in the developing mushroom body of the Drosophila brain (J. Plavicki and G. Boekhoff-Falk) (Click to enlarge)

Molecular and Cellular Pharmacology Graduate Program

The objective of the Graduate Program in Molecular and Cellular Pharmacology (MCP) is to equip students with expertise in cell biology and cell signaling cascades, with a focus on identifying targets and developing techniques for therapeutic interventions in human disease. Thus, students will develop the skills required to conduct state-of-the-art cell biology, biomolecular, biomedical, and pharmacological basic research: the fundamentals of Molecular and Cellular Pharmacology. Students who obtain a Ph.D. through the MCP Program (there is no formal MCP Masters degree) will be able to solve a variety of problems in basic biomedical sciences involving the design of research strategies for the discovery of novel drugs or gene therapy approaches to regulate signal transduction cascades and cellular behaviors. Patrica J. Keely, Ph.D., Associate Professor of Cell and Regenerative Biology, is the director of the this interdepartmental, interdisciplinary program. For further information regarding the MCP program, please visit the link below: Molecular and Cellular Pharmacology Graduate Program

Or contact: Lynn L. Squire Senior Student Services Coordinator Molecular and Cellular Pharmacology Graduate Program Room: 3770 Medical Sciences Center 1300 University Ave Madison, WI 53706 lsquire@wisc.edu (608) 262-9826

University of Wisconsin Stem Cell & Regenerative Medicine Center

Beginning in 1995 with the first successful culturing of embryonic stem cells from non-human primates, and later with the isolation of the world's first human embryonic stem cells, the University of Wisconsin-Madison has been a leader in the companion fields of stem cell research and regenerative medicine. The UW-Madison Stem Cell and Regenerative Medicine Center (SCRMC) is an umbrella organization operating under the School of Medicine and Public Health and the Graduate School. A number of faculty members of the Department of Cell and Regenerative Biology are also members of the SCRMC, which provides a central point of contact, information and facilitation for all stem cell research activities on campus. The center's mission is to advance the science of stem cell biology and foster breakthroughs in regenerative medicine through faculty interactions, research support and education. For further information regarding the MCP program, please visit the link below: http://stemcells.wisc.edu/

University of Wisconsin Cardiovascular Research Center

Cardiovascular research is an historically important aspect of research activities at the University of Wisconsin School of Medicine and Public Health.

See the article here:
Programs - Cell and Regenerative Biology, University of ...

Posted in Wisconsin Stem Cells | Comments Off on Programs – Cell and Regenerative Biology, University of …

Stem Cells Treatment Not Useful In Stroke Patients Finds Indian Study

Posted: November 18, 2014 at 6:40 am

A large-scale trial conducted in India has shown that stem cell therapy does not work in stroke patientsREUTERS

A study conducted on 120 patients in India has shown that stem cell treatment is not effective in treating paralysis resulting from a stroke.

The research which is thefirst large-scale study conducted in Indiacompared outcomes in those treated with stem cells to others and found no difference, reports Down to Earth.

While 60 patients with some form of disability of limbs caused by a stroke were given conventional treatment, an equal number received bone marrow stem cells in addition. All had experienced a stroke 3-4 weeks before the trial.

"We found that at the end of the first month, patients with stem cells showed more improvement compared to the control group. But at the end of the third month and one year, there was no difference," said Kameshwar Prasad, head, Department of Neurology, All India Institute of Medical Sciences (AIIMS), who led the study.

On an average 280 million bone marrow cells were injected, of which blood forming stem cells were around 2.9 million per patient.

The average age of patients in the study was around 50.

The study, published in the current issue of American journal Stroke, was conducted at AIIMS in New Delhi and four other hospitals covering four cities.

The study comes when many others have been suggesting that stem cells could help treat paralysis in stroke patients. The earlier study was done on a small number of patients as compared to the AIIMs study.

More research needs to be done, before stem cells are used in therapy as in India, many private clinics are openly offering stem cell treatment for various diseases.

Link:
Stem Cells Treatment Not Useful In Stroke Patients Finds Indian Study

Posted in Stem Cell Therapy | Comments Off on Stem Cells Treatment Not Useful In Stroke Patients Finds Indian Study

Page 1,934«..1020..1,9331,9341,9351,936..1,9401,950..»